These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 30240471

  • 1. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P.
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [Abstract] [Full Text] [Related]

  • 2. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
    Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW.
    Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
    Avezov SA, Mansurov FKh.
    Klin Med (Mosk); 2004 Jun; 82(3):55-8. PubMed ID: 15114777
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, Wu X, Zhang W, Ma H, You H, Jia J.
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [Abstract] [Full Text] [Related]

  • 5. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, Salemans JM, Tangerman A, van Buuren HR, van Hattum J, van Erpecum KJ.
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ.
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [Abstract] [Full Text] [Related]

  • 7. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A, Sesé P, Parés A.
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [Abstract] [Full Text] [Related]

  • 8. Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study.
    Zhu J, Shi Y, Zhou X, Li Z, Huang X, Han Z, Wang J, Wang R, Ding J, Wu K, Han Y, Fan D.
    Front Med; 2013 Jun; 7(2):255-63. PubMed ID: 23179137
    [Abstract] [Full Text] [Related]

  • 9. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
    Hirschfield GM, Beuers U, Kupcinskas L, Ott P, Bergquist A, Färkkilä M, Manns MP, Parés A, Spengler U, Stiess M, Greinwald R, Pröls M, Wendum D, Drebber U, Poupon R.
    J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
    [Abstract] [Full Text] [Related]

  • 10. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, Orchard RT, Theodossi A, Maxwell JD, Northfield TC.
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [Abstract] [Full Text] [Related]

  • 11. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR, Dutch PBC Study Group.
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [Abstract] [Full Text] [Related]

  • 12. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA, Sanai FM, Swain MG.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):813-20. PubMed ID: 16918885
    [Abstract] [Full Text] [Related]

  • 13. Decreased infiltration of CD4+ Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis.
    Yu K, Li P, Xu T, Xu J, Wang K, Chai J, Zhao D, Liu Y, Wang Y, Ma J, Fan L, Guo S, Li Z, Li M, Wang Z.
    Pathol Res Pract; 2021 Jan 01; 217():153291. PubMed ID: 33249399
    [Abstract] [Full Text] [Related]

  • 14. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Trivedi PJ, Hirschfield GM, Pares A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Hansen BE, Buuren HRV, van der Meer AJ.
    Gut; 2020 Aug 01; 69(8):1502-1509. PubMed ID: 31843787
    [Abstract] [Full Text] [Related]

  • 15. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
    Zhu H, Zheng M, He H, Lei H, Tai W, Yang J.
    BMC Gastroenterol; 2023 Nov 17; 23(1):400. PubMed ID: 37978445
    [Abstract] [Full Text] [Related]

  • 16. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V.
    J Hepatol; 2021 Jun 17; 74(6):1344-1354. PubMed ID: 33484775
    [Abstract] [Full Text] [Related]

  • 17. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
    Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM, Rossi SS, Hofmann AF, Baldus WP.
    Hepatology; 1995 Oct 17; 22(4 Pt 1):1158-62. PubMed ID: 7557866
    [Abstract] [Full Text] [Related]

  • 18. Ursodeoxycholic acid for primary biliary cirrhosis.
    Gluud C, Christensen E.
    Cochrane Database Syst Rev; 2002 Oct 17; (1):CD000551. PubMed ID: 11869580
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
    Van Hoogstraten HJ, De Smet MB, Renooij W, Breed JG, Engels LG, Den Ouden-Muller JW, Rijk MC, Smit AM, Zwertbroek R, Hop WC, van Berge Henegouwen GP, Schalm SW, van Buuren HR.
    Aliment Pharmacol Ther; 1998 Oct 17; 12(10):965-71. PubMed ID: 9798800
    [Abstract] [Full Text] [Related]

  • 20. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M.
    Am J Gastroenterol; 1990 Jan 17; 85(1):15-23. PubMed ID: 1967512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.